Journal
LIFE SCIENCES
Volume 315, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2022.121361
Keywords
Cancer; TP53; Mutated p53; Tumor microenvironment; Cancer-associated fibroblasts; Extracellular matrix
Ask authors/readers for more resources
TP53 is the most frequently mutated gene in human cancer, encoding the tumor suppressor protein p53. Mutations in TP53 gene impair p53 function, alter intracellular signaling pathways, and promote cancer development. Recent evidence suggests that p53 mutations also affect the tumor microenvironment (TME), composed of various cell types, and influence cancer progression by fine-tuning the inflammatory TME and cell fate reprogramming. Understanding how TP53 mutations reshape TME can provide insights for therapeutic strategies against cancer.
TP53 is the most frequently mutated gene in human cancer. It encodes the tumor suppressor protein p53, which suppresses tumorigenesis by acting as a critical transcription factor that can induce the expression of many genes controlling a plethora of fundamental cellular processes, including cell cycle progression, survival, apoptosis, and DNA repair. Missense mutations are the most frequent type of mutations in the TP53 gene. While these can have variable effects, they typically impair p53 function in a dominant-negative manner, thereby altering intracellular signaling pathways and promoting cancer development. Additionally, it is becoming increasingly apparent that p53 mutations also have non-cell autonomous effects that influence the tumor microenvironment (TME). The TME is a complex and heterogeneous milieu composed of both malignant and non-malignant cells, including cancer-associated fibroblasts (CAFs), adipocytes, pericytes, different immune cell types, such as tumorassociated macrophages (TAMs) and T and B lymphocytes, as well as lymphatic and blood vessels and extracellular matrix (ECM). Recently, a large body of evidence has demonstrated that various types of p53 mutations directly affect TME. They fine-tune the inflammatory TME and cell fate reprogramming, which affect cancer progression. Notably, re-educating the p53 signaling pathway in the TME may be an effective therapeutic strategy in combating cancer. Therefore, it is timely to here review the recent advances in our understanding of how TP53 mutations impact the fate of cancer cells by reshaping the TME.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available